Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem
Primary Purpose
Hypertension, Craniotomy
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Diltiazem
Labetalol
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, emergence, craniotomy, Hypertension during the emergence after craniotomy
Eligibility Criteria
Inclusion Criteria:
- patients who scheduled for craniotomy for tomor removal
Exclusion Criteria:
- allergic to labetalol or diltiazem
- Bradycardia < 60 beat/min
- Second or third degree heart block
- Severe asthma or severe COPD
- Brain stem tumor
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Diltiazem
Labetalol
Arm Description
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Outcomes
Primary Outcome Measures
The number of the patients who have systolic blood pressure below 140 mmHg
Secondary Outcome Measures
mean doses of the study drugs
the number of patients with Adverse Events as a Measure of Safety and Tolerability
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01408524
Brief Title
Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem
Official Title
A Comparative Study in the Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol (Avexa) and Diltiazem
Study Type
Interventional
2. Study Status
Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mahidol University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine the effectiveness of the antihypertensive drugs in the control of emergence blood pressure after tumor resection craniotomy; compared between labetalol (Avexa) and diltiazem (Herbessor).
Also the investigators seek to determine the effective dose of the antihypertensive drugs and their side effects in Thai population.
Detailed Description
The study was randomized equivalence trial
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Craniotomy
Keywords
Hypertension, emergence, craniotomy, Hypertension during the emergence after craniotomy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
184 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diltiazem
Arm Type
Active Comparator
Arm Description
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Arm Title
Labetalol
Arm Type
Active Comparator
Arm Description
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Intervention Type
Drug
Intervention Name(s)
Diltiazem
Other Intervention Name(s)
Herbessor
Intervention Description
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Intervention Type
Drug
Intervention Name(s)
Labetalol
Other Intervention Name(s)
Avexa
Intervention Description
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Primary Outcome Measure Information:
Title
The number of the patients who have systolic blood pressure below 140 mmHg
Time Frame
3 hours
Secondary Outcome Measure Information:
Title
mean doses of the study drugs
Time Frame
3hr
Title
the number of patients with Adverse Events as a Measure of Safety and Tolerability
Time Frame
6 hour
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients who scheduled for craniotomy for tomor removal
Exclusion Criteria:
allergic to labetalol or diltiazem
Bradycardia < 60 beat/min
Second or third degree heart block
Severe asthma or severe COPD
Brain stem tumor
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Busara - Sirivanasandha, MD
Organizational Affiliation
Department of Anesthesiology, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem
We'll reach out to this number within 24 hrs